2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke …
Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Blood-derived biomarkers for brain and spinal cord diseases are urgently needed. The
introduction of highly sensitive immunoassays led to a rapid increase in the number of …
introduction of highly sensitive immunoassays led to a rapid increase in the number of …
[HTML][HTML] Estándares SEA 2022 para el control global del riesgo cardiovascular
Resumen La Sociedad Española de Arteriosclerosis tiene entre sus objetivos contribuir al
mayor y mejor conocimiento de la enfermedad vascular, su prevención y su tratamiento. Es …
mayor y mejor conocimiento de la enfermedad vascular, su prevención y su tratamiento. Es …
[HTML][HTML] Actualización en diagnóstico y tratamiento del ataque cerebrovascular isquémico agudo
C García Alfonso, A Martínez Reyes, V García… - Universitas …, 2019 - scielo.org.co
El ataque cerebrovascular (ACV) agudo es la segunda causa de muerte en el mundo y
genera costos elevados en su tratamiento y recuperación, así como un gran impacto …
genera costos elevados en su tratamiento y recuperación, así como un gran impacto …
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy
Background Tenecteplase is an effective thrombolytic agent for eligible patients with stroke
who are treated within 4.5 hours after the onset of stroke. However, data regarding the …
who are treated within 4.5 hours after the onset of stroke. However, data regarding the …
[HTML][HTML] Trial of endovascular therapy for acute ischemic stroke with large infarct
X Huo, G Ma, X Tong, X Zhang, Y Pan… - … England Journal of …, 2023 - Mass Medical Soc
Background The role of endovascular therapy for acute stroke with a large infarction has not
been extensively studied in differing populations. Methods We conducted a multicenter …
been extensively studied in differing populations. Methods We conducted a multicenter …
[HTML][HTML] Trial of endovascular thrombectomy for large ischemic strokes
A Sarraj, AE Hassan, MG Abraham… - … England Journal of …, 2023 - Mass Medical Soc
Background Trials of the efficacy and safety of endovascular thrombectomy in patients with
large ischemic strokes have been carried out in limited populations. Methods We performed …
large ischemic strokes have been carried out in limited populations. Methods We performed …
[HTML][HTML] Trial of endovascular treatment of acute basilar-artery occlusion
C Tao, RG Nogueira, Y Zhu, J Sun, H Han… - … England Journal of …, 2022 - Mass Medical Soc
Background Data from trials investigating the effects and risks of endovascular
thrombectomy for the treatment of stroke due to basilar-artery occlusion are limited. Methods …
thrombectomy for the treatment of stroke due to basilar-artery occlusion are limited. Methods …
Reteplase versus alteplase for acute ischemic stroke
S Li, HQ Gu, H Li, X Wang, A **, S Guo… - … England Journal of …, 2024 - Mass Medical Soc
Background Alteplase is the standard agent used in early reperfusion therapy, but
alternative thrombolytic agents are needed. The efficacy and safety of reteplase as …
alternative thrombolytic agents are needed. The efficacy and safety of reteplase as …